What a Psychedelic Therapy Clinic Really Involves

Key Takeaways

• The Department of Veterans' Affairs announced a reported 740 million dollar veterans rehabilitation package that includes support for psychedelic-assisted therapy for eligible veterans with PTSD, with funding from 2025-26.
• A clinic sits on a stack of approvals: the authorised prescriber pathway at Commonwealth level plus state Schedule 8 permits, secure storage and sourcing obligations.
• More than 600 therapists are reported to have completed recognised training while reported patient numbers remain tiny, so the workforce is waiting on clinics that can lawfully treat.
• Supervision settings changed again in July 2026 and the TGA consulted on professional pathways in May 2026. The rules are actively moving.
• Who holds the authorisation is the structural question that decides key person risk, investability and what the clinic is worth.

1. 1.In Brief
2. 2.The Demand Side Is Arriving
3. 3.The Approval Stack
4. 4.The Workforce Puzzle
5. 5.The Question That Decides What the Clinic Is Worth
6. 6.Built for Moving Ground
7. 7.Frequently Asked Questions

The pitch deck version of a psychedelic therapy clinic is simple: Australia legalised prescribing first, programs are reported to charge around 30,000 dollars for a three dose MDMA course and the Department of Veterans' Affairs has announced a reported 740 million dollar veterans rehabilitation package that includes support for psychedelic-assisted therapy for eligible veterans with PTSD, with funding flowing from 2025-26. The operating reality is different. A psychedelic clinic is a stack of interlocking approvals, a workforce puzzle and a structure question, and every one of those layers moved within the last eighteen months.

In Brief

• Since 1 July 2023 authorised psychiatrists can prescribe MDMA for PTSD and psilocybin for treatment resistant depression, a world first that created the market a clinic serves.
• The demand signals are serious, including a reported 740 million dollar veterans package with support for psychedelic-assisted therapy for eligible veterans with PTSD.
• The clinic sits on an approval stack: the authorised prescriber pathway at Commonwealth level and Schedule 8 permits, secure storage and sourcing obligations at state level.
• More than 600 therapists are reported to have trained while reported patient numbers remain tiny, so the constraint is lawful treating capacity, not workforce enthusiasm.
• Supervision settings changed again in July 2026. A clinic designed against last year's rules can be wrong before it opens.

The Demand Side Is Arriving

For three years the question hanging over this sector was whether anyone beyond early adopters would pay. The answer is forming. Reported average charges of around 30,000 dollars for a three dose MDMA program show what the private market bears while capacity is scarce. The veterans package is the bigger signal: a reported 740 million dollar commitment that includes support for psychedelic-assisted therapy for eligible veterans with PTSD, with funding from 2025-26. When government money starts flowing toward a treatment, the clinics positioned to receive it lawfully are holding an asset the late arrivals cannot quickly replicate.

The Approval Stack

Everything in the clinic depends on prescribing, and prescribing runs through the authorised prescriber pathway: a specialist psychiatrist registered with the Medical Board, an evidence based clinical treatment protocol, approval from a human research ethics committee registered with the NHMRC and authorisation from the TGA, with RANZCP's training framework setting minimum expectations alongside. We have written separately about that pathway from the psychiatrist's side. From the clinic's side, the point is blunter: without it there is no service, and the clinic's timeline is hostage to how well that application is designed.

Then the state layer arrives. MDMA and psilocybin in a treatment setting are Schedule 8 territory, which brings permits, secure storage and sourcing obligations that attach to the premises, the people and the physical handling of the drug. These are not formalities layered on the Commonwealth approval. They are a separate regime with separate consequences, and they are where a clinic's day to day compliance is actually tested. A fit-out planned before the permit requirements are understood is a fit-out that gets done twice.

The Workforce Puzzle

Here is the strangest number in the sector. More than 600 therapists are reported to have completed recognised training, while reported figures show roughly 87 patients treated with MDMA-assisted therapy and 47 with psilocybin-assisted therapy as at September 2025. That is a workforce waiting for clinics, not clinics waiting for a workforce. For a founder it means the hiring market is favourable but the structural questions are live: what roles non-psychiatrist practitioners can hold, how they are engaged and supervised and how the clinic's model will map onto whatever the formal competency framework becomes. In May 2026 the TGA released targeted consultation findings on professional pathways for psychedelic-assisted therapy training, covering eligibility by professional registration, clinical experience and competency. The direction is clear even where the detail is not: the workforce rules are formalising, and contracts signed now should be drafted to survive that.

The Question That Decides What the Clinic Is Worth

Strip the sector to one structural issue and it is this: the authorisation attaches to the psychiatrist. The clinic's revenue, its veterans positioning and its investability all sit downstream of an approval held by a person who can resign. How the business is structured around that fact, what happens when the prescriber leaves, how a second prescriber is brought through the pathway and who controls the protocol, is the difference between a clinic that is a saleable business and one that is a practice with expensive furniture. Investors have started asking these questions at term sheet stage. Founders should have answers designed before then.

Built for Moving Ground

Supervision settings changed again in July 2026. The TGA consulted on professional pathways in May 2026. The rescheduling itself dates only to July 2023. Three moves in three years is not a settled field, and the clinics that last will be the ones whose structures were designed to absorb regulatory movement rather than resist it. That is a design brief, and the cheapest time to execute it is before the lease, the hires and the applications.

Frequently Asked Questions

Can a clinic operate without its own authorised prescriber?

Prescribing runs through authorised psychiatrists, so every treatment model has to be built around access to one. How that access is structured, employed, contracted or partnered, is one of the central design decisions and it carries the clinic's key person risk.

What approvals does a psychedelic clinic need beyond the TGA?

State Schedule 8 permits, secure storage and sourcing obligations apply on top of the Commonwealth pathway, and supervision settings changed again in July 2026. The state layer attaches to premises and practice, which makes it a fit-out and operations question as much as a legal one.

Is the veterans funding relevant to a private clinic?

The reported 740 million dollar package includes support for psychedelic-assisted therapy for eligible veterans with PTSD, with funding from 2025-26. Positioning to serve that demand lawfully is a strategic decision with structural consequences, and it rewards clinics that thought about it early.

What should I do before signing a lease or hiring?

Map the full approval stack, the workforce structure and the key person problem against your clinical model first. The sequencing decides your timeline, and a structure designed after commitments are made is a compromise from day one.

Building a psychedelic therapy clinic or investing in one? Visit our psychedelic clinic page, Contact Astris Law for a fixed fee feasibility consultation or call (07) 3519 5616.

This article is for general information purposes only and does not constitute legal advice and should not be relied on as such. While we take reasonable care to ensure the accuracy of the information provided, we make no representations or warranties as to its completeness, currency or reliability. We accept no liability for any loss or damage arising directly or indirectly from the use of, or reliance on, this website's content. You should always seek professional advice tailored to your specific circumstances before acting on any information in this article. Liability limited by a scheme approved under Professional Standards Legislation.